Navigation Links
MannKind Corporation to Hold Second Quarter Financial Results Conference Call on August 11, 2008
Date:8/4/2008

VALENCIA, Calif., Aug. 4 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) will release its 2008 second quarter financial results on Monday, August 11, 2008 at 4:00 p.m. EDT.

Management of the Company will host a conference call to discuss the second quarter financial results, clinical progress and other Company developments at 5:00 p.m. EDT on Monday, August 11, 2008. Presenting from the Company will be its Chairman and Chief Executive Officer, Alfred Mann; President and Chief Operating Officer, Hakan Edstrom; Corporate Vice President and Chief Financial Officer, Matthew Pfeffer and Corporate Vice President and Chief Scientific Officer, Peter Richardson.

To participate in the live call by telephone, please dial (888) 677-5721 or (210) 839-8507. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at http://www.mannkindcorp.com.

A telephone replay of the call will be accessible for approximately fourteen days following completion of the call by dialing (800) 219-6350 or (402) 220-3904. A replay will also be available on MannKind's website for fourteen days.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Its lead product, the Technosphere Insulin System, is currently in Phase 3 clinical trials in the United States
'/>"/>

SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. MannKind to Present at the UBS Global Life Sciences Conference
2. MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock
3. MannKind Announces Positive Results from a Phase 1a Study of a GLP-1 Formulation
4. MannKind to Present at the Piper Jaffray Healthcare Conference
5. MannKind to Present at the Wachovia 2008 Healthcare Conference
6. MannKind to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
7. MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on March 4, 2008
8. MannKind Corporation Response to Recent Market Events
9. Matthew J. Pfeffer Joins MannKind as Corporate Vice President and Chief Financial Officer
10. MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 5, 2008
11. MannKind to Present at the Morgan Stanley Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014  Orexigen Therapeutics, Inc. (Nasdaq: ... Day 180 List of Outstanding Issues (LOI) from the ... Use (CHMP) for the NB32 Marketing Authorization Application (MAA). ... an investigational drug candidate being evaluated for weight loss. ... 120 time point were adequately addressed by the Company ...
(Date:7/30/2014)... 2014 Researchers often use microelectronic devices ... such devices can do much more – perhaps ... researchers have looked to patterned assemblies of proteins ... engineering to characterize – and potentially control – ... envisioned to recreate animal and human physiological functions ...
(Date:7/30/2014)... , July 30, 2014  AtheroNova Inc. (OTCBB: ... and development of compounds to safely regress atherosclerotic ... announces that its partner, CardioNova, has accomplished first ... trial with AtheroNova,s lead compound, AHRO-001.  This Phase ... AHRO-001 Phase 1 safety trial completed in February ...
(Date:7/30/2014)... NCERC at Southern Illinois University ... findings on corn stover pretreatment methods at a ... Washington, D.C. , “Arun’s selection for presentation ... testament to the success of our postdoctoral fellowship ... the foresight and vision of SIUE and the ...
Breaking Biology Technology:Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 2UMD Researchers Bridge Gap between Microelectronics, Biological Systems 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 4AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 2NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 3
... victory for its client,Applera Corporation, a global leader in ... summary judgment ruling invalidating three key,contested life sciences patents. ... DNA sequencing reagents and instruments infringed,the patents in question. ... Bond Arterton of the,United States District Court for the ...
... a civil settlement with the U.S. Department of ... the federal False Claims Act,relating to Anzemet(R) involving ... The settlement relates to government claims that ... turn increased the cost of,government reimbursements for the ...
... 10 BioStorage Technologies, Inc.,(BST) announced that it ... Company (IPL) to purchase electricity generated by 100 ... voluntary,program. By offsetting the use of fossil-fueled power ... completely carbon-neutral by 2009. BST becomes the ...
Cached Biology Technology:Weil Gotshal Wins Major Victory for Applera; Secures Summary Judgment Invalidating Three Patents 2BioStorage Technologies Becomes Green Powered through the Use of 100% Certified Renewable Energy 2BioStorage Technologies Becomes Green Powered through the Use of 100% Certified Renewable Energy 3BioStorage Technologies Becomes Green Powered through the Use of 100% Certified Renewable Energy 4
(Date:7/30/2014)... spinal cord injury (SCI), traumatic brain injury (TBI) and ... has been learned over the past 30 years regarding ... regulate axon growth, but this large body of information ... Lemmon and his team from University of Miami in ... but a consensus is emerging that one contributing factor ...
(Date:7/30/2014)... analysis of the roughly 3,000 pieces is still in ... the results will be of major significance. "Amazingly often, ... species in Fushun amber that we found in Baltic ... , The Baltic amber comes from the Baltic Sea ... rich in finds are, e.g., the coastal regions of ...
(Date:7/30/2014)... Washington, DCToday scientists unveiled the first high-resolution map ... the entire country of Per. The new and ... a sea change for future market-based carbon economies. ... extremely high ecological diversity and it provides the ... degradation for conservation, land use, and enforcement purposes. ...
Breaking Biology News(10 mins):Chinese mosquitos on the Baltic Sea 2Peru's carbon quantified: Economic and conservation boon 2Peru's carbon quantified: Economic and conservation boon 3
... Deborah A. Frank, MD, the Director of the Grow ... a Professor of Pediatrics at Boston University School of ... from the National Institutes of Health to study the ... substance exposure (IUSE). The project, entitled Prenatal ...
... , Researchers at Yale School of Medicine have found ... type leads to Type 1 Gaucher disease, a rare ... in cells, resulting in liver/spleen enlargement, osteoporosis, bone pain, ... The new findings could lead to less expensive ...
... This release is available in French . , ... Neuro, McGill University have discovered that our brains have the ... processing specially-coded sounds, without any visual or tactile input. Not ... of the brain and how it perceives the world around ...
Cached Biology News:Cheaper, more effective treatment of type 1 Gaucher disease possible 2See no shape, touch no shape, hear a shape? 2
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
PURA Immunogen: PURA (NP_005850, 183 a.a. ~ 293 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rabbit polyclonal to CAMK 1D beta ( Abpromise for all tested applications). entrezGeneID: 57118 SwissProtID: Q5SQQ7...
Acetyl-Histone H2B (Lys20) Antibody...
Biology Products: